Archived article

Please note that tax, investment, pension and ISA rules can change and the information and any views contained in this article may now be inaccurate.

The £225m business will join the stock market on 17 August
Thursday 16 Aug 2018 Author: Lisa-Marie Janes

British healthcare technology firm Sensyne Health (SENS:AIM) has raised £60m to coincide with its stock market debut on 17 August. It will be valued at £225m when it starts trading on AIM.

Sensyne Health works with three NHS trusts by using its anonymous datasets for analysis, which can be used to improve patient care and speed up the discovery of new medicines.

It also licences its analysis to companies, which can help identify patients that may respond to certain treatments in clinical trials, identify new drug targets and help understand specific diseases.

Its NHS trust partners, Oxford, South Warwickshire and Chelsea & Westminster, collectively have a 10% stake in the company and receive 4% in royalties from licenced analysis.

The new money raised at its IPO (initial public offering) will be used to hire more doctors and computer scientists to analyse the data using clinical artificial intelligence and algorithms.

Sensyne has its sights set on 15 licences over the next few years, but investors should recognise potential risks such as competition and difficulty in attracting experts in artificial intelligence. (LMJ)

‹ Previous2018-08-16Next ›